7581 - 7590 of 8808 Results
Title
Year
-
OPENTitle: Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein DestabilizationJournal Name: Molecular NeurobiologyPublisher: Springer Science and Business Media LLCVol: 56Issue #: 8Start Page: 5273End Page: 5286Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1007/s12035-018-1449-2Best OA location URL: https://link.springer.com/content/pdf/10.1007/s12035-018-1449-2.pdfCitation Count: 18
-
OPENTitle: Open-source platforms to investigate analytical flexibility in neuroimagingJournal Name: Imaging NeurosciencePublisher: MIT PressVol: 3Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1162/imag.a.79Best OA location URL: https://direct.mit.edu/imag/article-pdf/doi/10.1162/IMAG.a.79/2534165/imag.a.79.pdfCitation Count: 0
-
OPENTitle: Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic NeurotransmissionJournal Name: CNS Neuroscience & TherapeuticsPublisher: WileyVol: 23Issue #: 2Start Page: 162End Page: 173Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1111/cns.12660Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cns.12660Citation Count: 28
-
RESTRICTEDTitle: Assessment of Wearing Off in Parkinson’s disease using objective measurementJournal Name: Journal of NeurologyPublisher: Springer Science and Business Media LLCVol: 268Issue #: 3Start Page: 914End Page: 922Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1007/s00415-020-10222-wCitation Count: 21
-
OPENTitle: Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's diseaseJournal Name: Neurobiology of DiseasePublisher: Elsevier BVVol: 64Issue #:Start Page: 79End Page: 87Publication Date:Open Access(OA) Status: OPENLicense: cc-by, cc-byDOI - Digital Object Identifier: 10.1016/j.nbd.2013.12.011Best OA location URL: https://doi.org/10.1016/j.nbd.2013.12.011Citation Count: 81
-
OPENTitle: The anti-parkinsonian drug zonisamide reduces neuroinflammation: Role of microglial Nav 1.6Journal Name: Experimental NeurologyPublisher: Elsevier BVVol: 308Issue #:Start Page: 111End Page: 119Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.expneurol.2018.07.005Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/7404626Citation Count: 38
- Chronic Pain in Parkinson’s Disease: Prevalence, Sex Differences, Regional Anatomy and Comorbidities2025OPENTitle: Chronic Pain in Parkinson’s Disease: Prevalence, Sex Differences, Regional Anatomy and ComorbiditiesJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/acn3.70174Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.70174Citation Count: 0
-
OPENTitle: Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s diseaseJournal Name: npj Parkinson's DiseasePublisher: Springer Science and Business Media LLCVol: 9Issue #: 1Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41531-023-00451-xBest OA location URL: https://www.nature.com/articles/s41531-023-00451-x.pdfCitation Count: 10
-
OPENTitle: Genetic Modifiers of Parkinson's Disease: A Case–Control StudyJournal Name: Annals of Clinical and Translational NeurologyPublisher: WileyVol:Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/acn3.70176Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acn3.70176Citation Count: 0
-
RESTRICTEDTitle: Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 18Issue #: 2Start Page: 145End Page: 154Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(18)30405-8Citation Count: 111